25 results on '"Finetti, Pascal"'
Search Results
2. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer.
- Author
-
Bertucci, François, De Nonneville, Alexandre, Finetti, Pascal, and Mamessier, Emilie
- Published
- 2023
- Full Text
- View/download PDF
3. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
- Author
-
de Nonneville, Alexandre, Salas, Sébastien, Bertucci, François, Sobinoff, Alexander P, Adélaïde, José, Guille, Arnaud, Finetti, Pascal, Noble, Jane R, Churikov, Dimitri, Chaffanet, Max, Lavit, Elise, Pickett, Hilda A, Bouvier, Corinne, Birnbaum, Daniel, Reddel, Roger R, and Géli, Vincent
- Abstract
In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high‐grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild‐type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT‐positive ATRX‐wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX‐mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX‐wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target. Synopsis: There is an urgent need to treat pediatric osteosarcomas that present high frequency of alternative lengthening of telomeres (ALT). This study identifies TOP3A amplification as mutually exclusive with ATRX inactivation, promoting ALT and TOP3A action at telomeres as a novel therapeutic target. 17p11 amplification and ATRX mutation are exclusive genomic events in ALT high‐grade pediatric osteosarcomas.TOP3A overexpression is a feature of ATRX‐wt ALT osteosarcomas.Over‐expression of TOP3A correlates with the presence of ATRX in ATRX‐wt ALT cell lines.TOP3A is required for proper BLM localization in ALT osteosarcoma cell lines and promotes ALT‐mediated telomeric DNA synthesis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients.
- Author
-
Aulas, Anaïs, Liberatoscioli, Maria Lucia, Finetti, Pascal, Cabaud, Olivier, Birnbaum, David J., Usclade, Lucas, Birnbaum, Daniel, Bertucci, François, and Mamessier, Emilie
- Published
- 2022
- Full Text
- View/download PDF
5. Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression.
- Author
-
Gouirand, Victoire, Gicquel, Tristan, Lien, Evan C, Jaune‐Pons, Emilie, Da Costa, Quentin, Finetti, Pascal, Metay, Elodie, Duluc, Camille, Mayers, Jared R, Audebert, Stephane, Camoin, Luc, Borge, Laurence, Rubis, Marion, Leca, Julie, Nigri, Jeremy, Bertucci, François, Dusetti, Nelson, Lucio Iovanna, Juan, Tomasini, Richard, and Bidaut, Ghislain
- Subjects
PANCREATIC cancer ,CANCER invasiveness ,KETONES ,PANCREATIC duct ,PANCREATIC tumors - Abstract
Pancreatic ductal adenocarcinoma (PDA) tumor cells are deprived of oxygen and nutrients and therefore must adapt their metabolism to ensure proliferation. In some physiological states, cells rely on ketone bodies to satisfy their metabolic needs, especially during nutrient stress. Here, we show that PDA cells can activate ketone body metabolism and that β‐hydroxybutyrate (βOHB) is an alternative cell‐intrinsic or systemic fuel that can promote PDA growth and progression. PDA cells activate enzymes required for ketogenesis, utilizing various nutrients as carbon sources for ketone body formation. By assessing metabolic gene expression from spontaneously arising PDA tumors in mice, we find HMG‐CoA lyase (HMGCL), involved in ketogenesis, to be among the most deregulated metabolic enzymes in PDA compared to normal pancreas. In vitro depletion of HMGCL impedes migration, tumor cell invasiveness, and anchorage‐independent tumor sphere compaction. Moreover, disrupting HMGCL drastically decreases PDA tumor growth in vivo, while βOHB stimulates metastatic dissemination to the liver. These findings suggest that βOHB increases PDA aggressiveness and identify HMGCL and ketogenesis as metabolic targets for limiting PDA progression. Synopsis: The molecular mechanisms underlying metabolic flexibility of solid tumor cells exposed to oxygen deprivation remain poorly understood. This study identifies the ketogenic enzyme HMG‐CoA lyase (HMGCL) and its derivative β‐hydroxybutyrate (βOHB) as essential drivers of pancreatic cancer, highlighting ketone body metabolism as a regulatory nexus in metastasis. Systemic βOHB is metabolized by pancreatic adenocarcinoma (PDA) cells, fueling the TCA cycle.HMGCL and βOHB promote PDA tumor aggressiveness and metastatic dissemination.Ketone body metabolic enzymes are upregulated in PDA.PDA cells de novo generate ketone bodies from various carbon sources.Depletion of HMGCL limits oncogenic properties of pancreatic tumor cells in vivo, which is rescued by exogenous βOHB. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion.
- Author
-
Villodre, Emilly S., Xiaoding Hu, Larson, Richard, Finetti, Pascal, Gomez, Kristen, Balema, Wintana, Stecklein, Shane R., Santiago-Sanchez, Ginette, Krishnamurthy, Savitri, Juhee Song, Xiaoping Su, Ueno, Naoto T., Tripathy, Debu, Van Laere, Steven, Bertucci, François, Vivas-Mejía, Pablo, Woodward, Wendy A., and Debeb, Bisrat G.
- Abstract
Inflammatory breast cancer (IBC) is an aggressive form of primary breast cancer characterized by rapid onset and high risk of metastasis and poor clinical outcomes. The biological basis for the aggressiveness of IBC is still not well understood and no IBC-specific targeted therapies exist. In this study, we report that lipocalin 2 (LCN2), a small secreted glycoprotein belonging to the lipocalin superfamily, is expressed at significantly higher levels in IBC vs non-IBC tumors, independently of molecular subtype. LCN2 levels were also significantly higher in IBC cell lines and in their culture media than in non-IBC cell lines. High expression was associated with poor-prognosis features and shorter overall survival in IBC patients. Depletion of LCN2 in IBC cell lines reduced colony formation, migration, and cancer stem cell populations in vitro and inhibited tumor growth, skin invasion, and brain metastasis in mouse models of IBC. Analysis of our proteomics data showed reduced expression of proteins involved in cell cycle and DNA repair in LCN2-silenced IBC cells. Our findings support that LCN2 promotes IBC tumor aggressiveness and offer a new potential therapeutic target for IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers.
- Author
-
Bertucci, François, Rypens, Charlotte, Finetti, Pascal, Guille, Arnaud, Adélaïde, José, Monneur, Audrey, Carbuccia, Nadine, Garnier, Séverine, Dirix, Piet, Gonçalves, Anthony, Vermeulen, Peter, Debeb, Bisrat G., Wang, Xiaoping, Dirix, Luc, Ueno, Naoto T., Viens, Patrice, Cristofanilli, Massimo, Chaffanet, Max, Birnbaum, Daniel, and Van Laere, Steven
- Abstract
Inflammatory breast cancer (IBC) is the most pro‐metastatic form of breast cancer. Better understanding of its pathophysiology and identification of actionable genetic alterations (AGAs) are crucial to improve systemic treatment. We aimed to define the DNA profiles of IBC vs noninflammatory breast cancer (non‐IBC) clinical samples in terms of copy number alterations (CNAs), mutations, and AGAs. We applied targeted next‐generation sequencing (tNGS) and array‐comparative genomic hybridization (aCGH) to 57 IBC and 50 non‐IBC samples and pooled these data with four public datasets profiled using NGS and aCGH, leading to a total of 101 IBC and 2351 non‐IBC untreated primary tumors. The respective percentages of each molecular subtype [hormone receptor‐positive (HR+)/HER2−, HER2+, and triple‐negative] were 68%, 15%, and 17% in non‐IBC vs 25%, 35%, and 40% in IBC. The comparisons were adjusted for both the molecular subtypes and the American Joint Committee on Cancer (AJCC) stage. The 10 most frequently altered genes in IBCs were TP53 (63%), HER2/ERBB2 (30%), MYC (27%), PIK3CA (21%), BRCA2 (14%), CCND1 (13%), GATA3 (13%), NOTCH1 (12%), FGFR1 (11%), and ARID1A (10%). The tumor mutational burden was higher in IBC than in non‐IBC. We identified 96 genes with an alteration frequency (p < 5% and q < 20%) different between IBC and non‐IBC, independently from the molecular subtypes and AJCC stage; 95 were more frequently altered in IBC, including TP53, genes involved in the DNA repair (BRCA2) and NOTCH pathways, and one (PIK3CA) was more frequently altered in non‐IBC. Ninety‐seven percent of IBCs displayed at least one AGA. This percentage was higher than in non‐IBC (87%), notably for drugs targeting DNA repair, NOTCH signaling, and CDK4/6, whose pathways were more frequently altered (DNA repair) or activated (NOTCH and CDK4/6) in IBC than in non‐IBC. The genomic landscape of IBC is different from that of non‐IBC. Enriched AGAs in IBC may explain its aggressiveness and provide clinically relevant targets. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer.
- Author
-
de Nonneville, Alexandre, Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
TRIPLE-negative breast cancer , *PROGNOSIS , *CANCER cells , *BREAST cancer - Abstract
We then investigated the consequence of WEE1 chemical inhibition, which is less drastic than the WEE1 knock-out, in breast cancer cell lines according to the TN/non-TN subtypes. C/ Kaplan-Meier metastasis-free survival (MFS) in patients with breast cancer (n = 3454) according to the WEE1 expression-based class in TNBC (red curves) and in non-TNBC (blue curves). TNBC is the most aggressive molecular subtype of breast cancer, but patients with TNBC have less benefited from recognized molecular targets than patients with other subtypes. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
9. PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target.
- Author
-
Bertucci, François, Finetti, Pascal, Monneur, Audrey, Perrot, Delphine, Chevreau, Christine, Le Cesne, Axel, Blay, Jean‐Yves, Mir, Olivier, and Birnbaum, Daniel
- Abstract
Soft tissue sarcomas (STSs) are aggressive tumors with few efficient systemic therapies. Poly(ADP‐ribose) polymerase‐1 (PARP1) inhibitors represent an emerging therapeutic option in tumors with genomic instability. The genomics of STSs is complex in more than half of cases, suggesting a high level of inherent DNA damage and genomic instability. Thus, STSs could be efficiently targeted with PARP inhibitors. Promising preclinical results have been reported, but few data are available regarding PARP1 expression in clinical samples. We examined PARP1 mRNA expression in 1464 clinical samples of STS, including 1432 primary tumors and 32 relapses, and searched for correlations with clinicopathological features, including metastasis‐free survival (MFS). Expression was heterogeneous across the samples, not different between primary and secondary tumors, and was correlated to PARP1 DNA copy number. In the 1432 primary tumors, the 'PARP1‐high' samples were associated with younger patients, more frequent locations at the extremities, superficial trunk and head and neck, more leiomyosarcomas and other STSs and less liposarcomas and myxofibrosarcomas, more grade 3, more high‐risk CINSARC tumors, and more 'chromosomically instable' tumors. They were associated with shorter MFS, independently of other significant prognostic features, including the CINSARC signature. We found a strong involvement of genes overexpressed in the 'PARP1‐high' samples in cell cycle, DNA replication, and DNA repair. PARP1 expression refines the prediction of MFS in STSs, and similar expression exists in secondary and primary tumors, supporting the development of PARP1 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
- Author
-
Jansen, Maurice P.H.M., Sas, Leen, Sieuwerts, Anieta M., Van Cauwenberghe, Caroline, Ramirez-Ardila, Diana, Look, Maxime, Ruigrok-Ritstier, Kirsten, Finetti, Pascal, Bertucci, François, Timmermans, Mieke M., van Deurzen, Carolien H.M., Martens, John W.M., Simon, Iris, Roepman, Paul, Linn, Sabine C., van Dam, Peter, Kok, Marleen, Lardon, Filip, Vermeulen, Peter B., and Foekens, John A.
- Abstract
Background Patients with Estrogen Receptor α-positive (ER+) Inflammatory Breast Cancer (IBC) are less responsive to endocrine therapy compared with ER+ non-IBC (nIBC) patients. The study of ER+ IBC samples might reveal biomarkers for endocrine resistant breast cancer. Materials & methods Gene expression profiles of ER+ samples from 201 patients were explored for genes that discriminated between IBC and nIBC. Classifier genes were applied onto clinically annotated expression data from 947 patients with ER+ breast cancer and validated with RT-qPCR for 231 patients treated with first-line tamoxifen. Relationships with metastasis-free survival (MFS) and progression-free survival (PFS) following adjuvant and first-line endocrine treatment, respectively, were investigated using Cox regression analysis. Results A metagene of six genes including the genes encoding for 4-aminobutyrate aminotransferase ( ABAT ) and Stanniocalcin-2 ( STC2 ) were identified to distinguish 22 ER+ IBC from 43 ER+ nIBC patients and remained discriminatory in an independent series of 136 patients. The metagene and two genes were not prognostic in 517 (neo)adjuvant untreated lymph node-negative ER+ nIBC breast cancer patients. Only ABAT was related to outcome in 250 patients treated with adjuvant tamoxifen. Three independent series of in total 411 patients with advanced disease showed increased metagene scores and decreased expression of ABAT and STC2 to be correlated with poor first-line endocrine therapy outcome. The biomarkers remained predictive for first-line tamoxifen treatment outcome in multivariate analysis including traditional factors or published signatures. In an exploratory analysis, ABAT and STC2 protein expression levels had no relation with PFS after first-line tamoxifen. Conclusions This study utilized ER+ IBC to identify a metagene including ABAT and STC2 as predictive biomarkers for endocrine therapy resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.
- Author
-
Allensworth, Jennifer L., Evans, Myron K., Bertucci, François, Aldrich, Amy J., Festa, Richard A., Finetti, Pascal, Ueno, Naoto T., Safi, Rachid, McDonnell, Donald P., Thiele, Dennis J., Van Laere, Steven, and Devi, Gayathri R.
- Abstract
Cancer cells often have increased levels of reactive oxygen species (ROS); however, acquisition of redox adaptive mechanisms allows for evasion of ROS-mediated death. Inflammatory breast cancer (IBC) is a distinct, advanced BC subtype characterized by high rates of residual disease and recurrence despite advances in multimodality treatment. Using a cellular model of IBC, we identified an oxidative stress response (OSR) signature in surviving IBC cells after administration of an acute dose of an ROS inducer. Metagene analysis of patient samples revealed significantly higher OSR scores in IBC tumor samples compared to normal or non-IBC tissues, which may contribute to the poor response of IBC tumors to common treatment strategies, which often rely heavily on ROS induction. To combat this adaptation, we utilized a potent redox modulator, the FDA-approved small molecule Disulfiram (DSF), alone and in combination with copper. DSF forms a complex with copper (DSF-Cu) increasing intracellular copper concentration both in vitro and in vivo , bypassing the need for membrane transporters. DSF-Cu antagonized NFκB signaling, aldehyde dehydrogenase activity and antioxidant levels, inducing oxidative stress-mediated apoptosis in multiple IBC cellular models. In vivo , DSF-Cu significantly inhibited tumor growth without significant toxicity, causing apoptosis only in tumor cells. These results indicate that IBC tumors are highly redox adapted, which may render them resistant to ROS-inducing therapies. DSF, through redox modulation, may be a useful approach to enhance chemo- and/or radio-sensitivity for advanced BC subtypes where therapeutic resistance is an impediment to durable responses to current standard of care. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization.
- Author
-
Bertucci, François, Bouvier‐Labit, Corinne, Finetti, Pascal, Adélaïde, José, Metellus, Philippe, Mokhtari, Karima, Decouvelaere, Anne‐Valérie, Miquel, Catherine, Jouvet, Anne, Figarella‐Branger, Dominique, Pedeutour, Florence, Chaffanet, Max, and Birnbaum, Daniel
- Published
- 2013
- Full Text
- View/download PDF
13. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
- Author
-
Brecqueville, Mandy, Rey, Jérôme, Bertucci, François, Coppin, Emilie, Finetti, Pascal, Carbuccia, Nadine, Cervera, Nathalie, Gelsi-Boyer, Véronique, Arnoulet, Christine, Gisserot, Olivier, Verrot, Denis, Slama, Borhane, Vey, Norbert, Mozziconacci, Marie-Joelle, Birnbaum, Daniel, and Murati, Anne
- Published
- 2012
- Full Text
- View/download PDF
14. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
- Author
-
Jacquemier, Jocelyne, Bertucci, François, Finetti, Pascal, Esterni, Benjamin, Charafe-Jauffret, Emmanuelle, Thibult, Marie-Laure, Houvenaeghel, Gilles, Van den Eynde, Benoit, Birnbaum, Daniel, Olive, Daniel, and Xerri, Luc
- Abstract
Medullary breast cancer (MBC) is a basal-like breast carcinoma (BLBC) with a favourable outcome, whereas nonmedullary BLBC has a poor prognosis. Tumour infiltrating lymphocytes (TILs) are present in both MBC and BLBC. We hypothesized that the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) could modulate the TILs effects among these tumours and explain their different outcomes. The amount of TILs and IDO expression were analysed using immunohistochemistry (IHC) in 155 BC cases including MBC (n = 17), atypical MBC (n = 13) and non-MBC (n = 125). Messenger RNA expression of the INDO gene, which encodes IDO, was measured in 262 cases from our institution. INDO mRNA expression and histoclinical data of 1,487 BC cases were collected from public databases. IDO immunostaining was present in both neoplastic and stromal cells in 100% of MBC and was associated with histological medullary features among non-MBC cases. There was a significant correlation between IDO positivity and TIL amounts. In our series including mostly grade-3 BC, IDO immunostaining was the most significant marker (p = 0.02) associated with better survival in multivariate analysis. Among our 262 analysed BC cases, INDO mRNA showed significant overexpression in BLBC as compared to luminal A tumours, and in MBC as compared to basallike non-MBC. In the pooled series of 1,749 BC cases, INDO mRNA was overexpressed in BLBC and was the most significant predictor of better survival in this subtype using multivariate analysis (p = 0.0024). In conclusion, high IDO expression is associated with morphological medullary features and has an independent favourable prognostic value in BLBC. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Genome profiling of pancreatic adenocarcinoma.
- Author
-
Birnbaum, David J., Adélaïde, José, Mamessier, Emilie, Finetti, Pascal, Lagarde, Arnaud, Monges, Geneviève, Viret, Frédéric, Gonçalvès, Anthony, Turrini, Olivier, Delpero, Jean-Robert, Iovanna, Juan, Giovannini, Marc, Birnbaum, Daniel, and Chaffanet, Max
- Published
- 2011
- Full Text
- View/download PDF
16. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.
- Author
-
Sircoulomb, Fabrice, Nicolas, Nathalie, Ferrari, Anthony, Finetti, Pascal, Bekhouche, Ismahane, Rousselet, Estelle, Lonigro, Aurélie, Adélaïde, José, Baudelet, Emilie, Esteyriès, Séverine, Wicinski, Julien, Audebert, Stéphane, Charafe-Jauffret, Emmanuelle, Jacquemier, Jocelyne, Lopez, Marc, Borg, Jean-Paul, Sotiriou, Christos, Popovici, Cornel, Bertucci, François, and Birnbaum, Daniel
- Abstract
Luminal B breast cancers represent a fraction of oestrogen receptor (ER)-positive tumours associated with poor recurrence-free and disease-specific survival in all adjuvant systemic treatment categories including hormone therapy alone. Identification of specific signalling pathways driving luminal B biology is paramount to improve treatment. We have studied 100 luminal breast tumours by combined analysis of genome copy number aberrations and gene expression. We show that amplification of the ZNF703 gene, located in chromosomal region 8p12, preferentially occurs in luminal B tumours. We explored the functional role of ZNF703 in luminal B tumours by overexpressing ZNF703 in the MCF7 luminal cell line. Using mass spectrometry, we identified ZNF703 as a co-factor of a nuclear complex comprising DCAF7, PHB2 and NCOR2. ZNF703 expression results in the activation of stem cell-related gene expression leading to an increase in cancer stem cells. Moreover, we show that ZNF703 is implicated in the regulation of ER and E2F1 transcription factor. These findings point out the prominent role of ZNF703 in transcription modulation, stem cell regulation and luminal B oncogenesis. →See accompanying Closeup by Vessela Kristensen DOI [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
- Author
-
Sabatier, Renaud, Adélaïde, José, Finetti, Pascal, Ferrari, Anthony, Huiart, Laetitia, Sobol, Hagay, Chaffanet, Max, Birnbaum, Daniel, and Bertucci, François
- Published
- 2010
- Full Text
- View/download PDF
18. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia V. Gelsi-Boyer et al Gene Mutations in CMML.
- Author
-
Gelsi-Boyer, Véronique, Trouplin, Virginie, Roquain, Julien, Adélaïde, José, Carbuccia, Nadine, Esterni, Benjamin, Finetti, Pascal, Murati, Anne, Arnoulet, Christine, Zerazhi, Hacène, Fezoui, Hacène, Tadrist, Zoulika, Nezri, Meyer, Chaffanet, Max, Mozziconacci, Marie-Joëlle, Vey, Norbert, and Birnbaum, Daniel
- Subjects
GENETIC mutation ,LEUKEMIA ,GENES ,HEMATOLOGY ,MYELOPROLIFERATIVE neoplasms - Abstract
Chronic myelomonocytic leukaemia (CMML) is a haematological disease currently classified in the category of myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) because of its dual clinical and biological presentation. The molecular biology of CMML is poorly characterized. We studied a series of 53 CMML samples including 31 cases of myeloproliferative form (MP-CMML) and 22 cases of myelodysplastic forms (MD-CMML) using array-comparative genomic hybridisation (aCGH) and sequencing of 13 candidate genes including ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2 and WT1. Mutations in ASXL1 and in the genes associated with proliferation (CBL, FLT3, PTPN11, NRAS) were mainly found in MP-CMML cases. Mutations of ASXL1 correlated with an evolution toward an acutely transformed state: all CMMLs that progressed to acute phase were mutated and none of the unmutated patients had evolved to acute leukaemia. The overall survival of ASXL1 mutated patients was lower than that of unmutated patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. Gene Expression Profiling of Inflammatory Breast Cancer.
- Author
-
Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, and Viens, Patrice
- Subjects
- *
INFLAMMATORY breast cancer , *GENE expression , *DNA microarrays , *CLUSTER analysis (Statistics) , *CANCER education , *RNA - Abstract
The article presents a study on the conduction of gene expression profiling studies on inflammatory breast cancer (IBC) clinical samples. The study focused on IBC and non-IBC profile samples and results showed the feasibility of messenger RNA expression from IBC biopsies and great transcriptional heterogeneity of IBC and the existence of molecular subtypes similar to non-IBC. It is concluded that there is a need for larger series of IBC samples using homogenous criteria.
- Published
- 2010
- Full Text
- View/download PDF
20. How different are luminal A and basal breast cancers?
- Author
-
Bertucci, François, Finetti, Pascal, Cervera, Nathalie, Charafe-Jauffret, Emmanuelle, Buttarelli, Max, Jacquemier, Jocelyne, Chaffanet, Max, Maraninchi, Dominique, Viens, Patrice, and Birnbaum, Daniel
- Published
- 2009
- Full Text
- View/download PDF
21. How basal are triple-negative breast cancers?
- Author
-
Bertucci, François, Finetti, Pascal, Cervera, Nathalie, Esterni, Benjamin, Hermitte, Fabienne, Viens, Patrice, and Birnbaum, Daniel
- Abstract
The basal molecular subtype of breast cancer (BC) is defined by the mRNA expression pattern of an intrinsic ∼500-gene set. It is the most homogeneous subtype in transcriptional terms, and one of the most aggressive in prognostic terms. Clinical trials testing new systemic therapeutic strategies have been launched in basal BCs. Although no proof of evidence has yet been reported, basal tumors are currently assimilated to and selected as triple-negative (TN) BCs in these trials because of their frequent immunohistochemical (IHC) negativity for hormone and ERBB2 receptors. Here, we have assessed the degrees of correlation and of homogeneity of the TN phenotype (IHC-based definition) and the basal subtype (gene expression-based definition). We analyzed 172 TN BCs defined by gene expression profile as basal (123 cases) and nonbasal (49 cases). Conversely, 160 tumors were defined as basal by their gene expression profile and included 123 TN and 37 non-TN samples. Uni- and multivariate analyses revealed that TN BCs represent a more heterogeneous group than basal BCs, including basal and nonbasal tumors very different both at the histoclinical and molecular level, notably for mRNA expression of molecules targeted by specific therapies under evaluation in clinical trials. These results call for caution in the interpretation of ongoing trials and selection of patients in future trials. They also warrant the identification of molecular markers for basal BCs more clinically applicable than gene expression profiles. © 2008 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
22. Moesin expression is a marker of basal breast carcinomas.
- Author
-
Charafe-Jauffret, Emmanuelle, Monville, Florence, Bertucci, François, Esterni, Benjamin, Ginestier, Christophe, Finetti, Pascal, Cervera, Nathalie, Geneix, Jeannine, Hassanein, Mohamed, Rabayrol, Laetitia, Sobol, Hagay, Taranger-Charpin, Colette, Xerri, Luc, Viens, Patrice, Birnbaum, Daniel, and Jacquemier, Jocelyne
- Abstract
Basal breast cancers (BBCs) have a high risk of metastasis, recurrence and death. Formal subtype definition relies on gene expression but can be approximated by protein expression. New markers are needed to help in the management of the basal subtype of breast cancer. In a previous transcriptional analysis of breast cell lines we found that Moesin expression was a potential basal marker. We show here that Moesin protein expression is a basal marker in breast tumors. In a tissue microarray (TMA) containing 547 sporadic breast cancers, of which 108 were profiled for gene expression, Moesin was expressed in 31% of all tumors and in 82% of the basal tumors. To confirm that Moesin expression remained associated with the basal phenotype in specific types of BBCs, we analyzed Moesin expression in 2 other TMAs containing 40 medullary breast cancers (MBCs) and 27 BRCA1-associated breast cancers (BRCA1-BCs), respectively. Moesin was strongly expressed in MBCs (87%; p = 2.4 × 10 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
23. Absence of ESR1 amplification in a series of breast cancers.
- Author
-
Adélaïde, José, Finetti, Pascal, Charafe-Jauffret, Emmanuelle, Wicinski, Julien, Jacquemier, Jocelyne, Sotiriou, Christos, Bertucci, François, Birnbaum, Daniel, and Chaffanet, Max
- Published
- 2008
- Full Text
- View/download PDF
24. A genome‐wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.
- Author
-
Arfaoui, Abir, Rioualen, Claire, Azzoni, Violette, Pinna, Guillaume, Finetti, Pascal, Wicinski, Julien, Josselin, Emmanuelle, Macario, Manon, Castellano, Rémy, Léonard‐Stumpf, Candi, Bal, Anthony, Gros, Abigaelle, Lossy, Sylvain, Kharrat, Maher, Collette, Yves, Bertucci, Francois, Birnbaum, Daniel, Douik, Hayet, Bidaut, Ghislain, and Charafe‐Jauffret, Emmanuelle
- Abstract
Therapeutic resistance is a major clinical challenge in oncology. Evidence identifies cancer stem cells (CSCs) as a driver of tumor evolution. Accordingly, the key stemness property unique to CSCs may represent a reservoir of therapeutic target to improve cancer treatment. Here, we carried out a genome‐wide RNA interference screen to identify genes that regulate breast CSCs‐fate (bCSC). Using an interactome/regulome analysis, we integrated screen results in a functional mapping of the CSC‐related processes. This network analysis uncovered potential therapeutic targets controlling bCSC‐fate. We tested a panel of 15 compounds targeting these regulators. We showed that mifepristone, salinomycin, and JQ1 represent the best anti‐bCSC activity. A combination assay revealed a synergistic interaction of salinomycin/JQ1 association to deplete the bCSC population. Treatment of primary breast cancer xenografts with this combination reduced the tumor‐initiating cell population and limited metastatic development. The clinical relevance of our findings was reinforced by an association between the expression of the bCSC‐related networks and patient prognosis. Targeting bCSCs with salinomycin/JQ1 combination provides the basis for a new therapeutic approach in the treatment of breast cancer. Synopsis: The development of cancer stem cell‐targeting therapies is of major interest and requires insight into the underlying mechanisms. In this study, a genome‐wide RNAi screen was established, and revealed essential therapeutic targets of breast cancer stem cells (bCSC). bCSC‐related processes were identified by functional mapping integrating RNAi screens.bCSC‐related processes represented a reservoir of therapeutic target.Salinomycin synergized with JQ1 treatment to reduce the bCSC population and limit tumor progression.bCSC‐related processes were associated with poor prognosis in breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.
- Author
-
Nonneville, Alexandre, Kalbacher, Elsa, Cannone, Francesco, Guille, Arnaud, Adelaïde, José, Finetti, Pascal, Cappiello, Maria, Lambaudie, Eric, Ettore, Giuseppe, Charafe, Emmanuelle, Mamessier, Emilie, Provansal, Magali, Bertucci, François, and Sabatier, Renaud
- Subjects
- *
GENE expression , *DNA analysis , *GENE expression profiling , *PROTEIN expression , *CARCINOMA , *UTERINE tumors , *ENDOMETRIUM - Abstract
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers. We collected clinical data and formalin‐fixed paraffin‐embedded (FFPE) samples for analysis at the DNA level using panel‐based next‐generation sequencing and array‐comparative genomic hybridization. Additionally, we examined mRNA expression using NanoString nCounter® and protein expression through tissue microarray. We compared EOvC with other ovarian subtypes and uterine endometrioid tumors. Furthermore, we assessed the impact of molecular alterations on patient outcomes, including progression‐free survival (PFS) and overall survival (OS). Preliminary analysis of clinical data from 668 patients, including 86 (12.9%) EOvC, revealed more favorable prognosis for EOvC compared with serous ovarian carcinoma (5‐year OS of 60% versus 45%; P = 0.001) driven by diagnosis at an earlier stage. Immunohistochemistry and copy number alteration (CNA) profiles of 43 cases with clinical data and FFPE samples available indicated that EOvC protein expression and CNA profiles were more similar to endometrioid endometrial tumors than to serous ovarian carcinomas. EOvC exhibited specific alterations, such as lower rates of PTEN loss, mutations in DNA repair genes, and P53 abnormalities. Survival analysis showed that patients with tumors harboring loss of PTEN expression had worse outcomes (median PFS 19.6 months vs. not reached; P = 0.034). Gene expression profile analysis confirmed that EOvC differed from serous tumors. However, comparison to other rare subtypes of ovarian cancer suggested that the EOvC transcriptomic profile was close to that of ovarian clear cell carcinoma. Downregulation of genes involved in the PI3K pathway and DNA methylation was observed in EOvC. In conclusion, EOvC represents a distinct biological entity and should be regarded as such in the development of specific clinical approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.